Search This Blog

Thursday, July 30, 2026

Sanofi beats as Dupixent global Q2 net sales climb 38%

 

Sanofi's Dupixent global Q2 net sales climb 38% to about $6B, beat LSEG $5.34B estimate

  • Regeneron reported global second-quarter net sales of eczema drug Dupixent, which are recorded by partner Sanofi.
  • Sanofi ADR is scheduled to announce earnings today before market open.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)